Citigroup
ODT

Citigroup’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Citigroup’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,959
Closed -$6K – 6217
2021
Q3 		$6K Sell
1,959
-375
-16% -$1.25K ﹤0.01% 5576
2021
Q2 		$8K Sell
2,334
-187,910
-99% -$645K ﹤0.01% 5752
2021
Q1 		$651K Buy
190,244
+181,550
+2,088% +$3.43M ﹤0.01% 3281
2020
Q4 		$167K Buy
8,694
+7,881
+969% +$122K ﹤0.01% 5128
2020
Q3 		$11K Sell
813
-19,041
-96% -$539K ﹤0.01% 6588
2020
Q2 		$841K Buy
19,854
+17,057
+610% +$552K ﹤0.01% 3740
2020
Q1 		$77K Buy
2,797
+399
+17% +$11.6K ﹤0.01% 5586
2019
Q4 		$78K Buy
2,398
+1,339
+126% +$41.5K ﹤0.01% 5973
2019
Q3 		$28K Sell
1,059
-1,111
-51% -$37.2K ﹤0.01% 6535
2019
Q2 		$80K Buy
2,170
+330
+18% +$7.91K ﹤0.01% 6075
2019
Q1 		$41K Buy
1,840
+52
+3% +$909 ﹤0.01% 6499
2018
Q4 		$25K Sell
1,788
-74
-4% -$1.15K ﹤0.01% 6768
2018
Q3 		$36K Buy
1,862
+886
+91% +$18.1K ﹤0.01% 6786
2018
Q2 		$22K Buy
976
+86
+10% +$2K ﹤0.01% 6877
2018
Q1 		$19K Buy
+890
New +$21K ﹤0.01% 6781

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Citigroup's ODT Position: Q4 2021 in Review

Citigroup sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 1,959 shares — an estimated $6K sold.

Citigroup first reported a position in ODT in Q1 2018 and held it in 15 quarters. The position peaked at $841K in Q2 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Citigroup reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Citigroup sold 1,959 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $6K.
  • Citigroup first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
  • Citigroup's Odonate Therapeutics, Inc. Common Stock position peaked at $841K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.